The Use of Light Therapy for Managing Sleep Disturbances in Patients With Advanced Cancer
Primary Purpose
Advanced Cancers
Status
Terminated
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
Bright Light Therapy
Dim Red Light Therapy
Questionnaires
Study Diaries
Red Light Litebook
Bright Light Litebook
Sponsored by
About this trial
This is an interventional treatment trial for Advanced Cancers focused on measuring Sleep Disturbances, Depression, Anxiety, Fatigue, Quality of life
Eligibility Criteria
Inclusion Criteria:
- Advanced cancer patients seen in Supportive Care outpatient clinic at M.D. Anderson Cancer Center, with average sleep disturbance >=4 out of 10 for at least one week
- Age 18 or greater
- Karnofsky performance status score of >=40 at time of inclusion into study
- Agrees to return to MD Anderson Cancer Center (MDACC) for follow-up visits
- English speaking
Exclusion Criteria:
- Persons with congenital blindness and self-reported acquired blindness (independent of the cause) with no light perception
- Patients with a history of retinal disease
- Patients with a current diagnosis of major depression disorder or generalized anxiety disorder
- Patients who have received light therapy in the past either as part of treatment for other disorders or as a study subject
- Patients currently on amiodarone, thiazide diuretics or epidermal growth factor receptor (EGFR) inhibitors (erlotinib, gefitinib, cetuximab, panitumumab)
- Patients who are currently receiving ultraviolet A light/ultraviolet B light (UVA/UVB) therapy or tanning sessions at salons
- Patients with a diagnosis of obstructive sleep apnea or narcolepsy
- Patients with >2 hours of direct exposure to outdoor natural light per day (light exposure diary -- screening).
Sites / Locations
- University of Texas MD Anderson Cancer Center
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Placebo Comparator
Arm Label
Bright Light Therapy
Dim Red Light Therapy
Arm Description
Daily Bright Light Therapy using Bright Light Litebook device for two 14 day periods.
Daily Dim Red Light Therapy (placebo) using control Red Light Litebook device for 14 days then proceed to the open label phase and receive daily bright light for 14 days.
Outcomes
Primary Outcome Measures
Effect of Bright Light Therapy on Sleep Disturbances Compared to Dim Red Light in Patients With Advanced Cancer Followed at a Palliative Care Outpatient Clinic at a Comprehensive Cancer Center
Pittsburgh Sleep Quality Index (PSQI) measured at baseline and two weeks. The PSQI is a validated tool for insomnia, an effective instrument for measuring the quality and patterns of sleep using a 19-item questionnaire. It differentiates "poor" from "good" sleep by measuring seven areas: subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleeping medication, and daytime dysfunction over the last month. Each area is rated from 0-3 with the higher score reflecting more severe sleep complaints. The addition of all scores permits the analysis of the participant's overall sleep experience. The PSQI global score ranges from 0 to 21, with a score of 5 or greater indicating significant sleep disturbance.
Secondary Outcome Measures
Full Information
NCT ID
NCT01193530
First Posted
August 31, 2010
Last Updated
March 25, 2019
Sponsor
M.D. Anderson Cancer Center
1. Study Identification
Unique Protocol Identification Number
NCT01193530
Brief Title
The Use of Light Therapy for Managing Sleep Disturbances in Patients With Advanced Cancer
Official Title
The Use of Light Therapy for Managing Sleep Disturbances in Patients With Advanced Cancer
Study Type
Interventional
2. Study Status
Record Verification Date
March 2019
Overall Recruitment Status
Terminated
Why Stopped
Low Accrual
Study Start Date
June 2011 (undefined)
Primary Completion Date
March 2016 (Actual)
Study Completion Date
March 2016 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
M.D. Anderson Cancer Center
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The goal of this research study is to learn if a type of light therapy can be used to help patients with advanced cancer who are having difficulty sleeping to sleep better.
Detailed Description
Study Groups:
If you are found to be eligible to take part in this study, you will be randomly assigned (as in the flip of a coin) to one of two groups:
Group 1 will receive one type of light therapy for 30 minutes every day for 14 days.
Group 2 will receive a placebo light for 30 minutes every day for 14 days. The placebo light is not designed to have any effect on your sleep.
You will not know which group you are in. After 14 days, both groups will begin receiving the light therapy for another 14 days.
Litebook:
You will use a device called a Litebook to receive either the light therapy or the placebo light for 30 minutes, within 2 hours of waking up every day. The Litebook is about the size of a deck of cards. To use the Litebook, you will place it on a table within 2 feet of you while you are sitting down. The Litebook will either deliver the light therapy or the placebo light. You do not need to look directly into the Litebook and you can do usual activities such as eating or reading while you are using it. The study staff will teach you how to use the Litebook.
Study Diaries:
You will complete the following diaries at the end of each day of the 28-day study period:
The light exposure diary about how much light you were exposed to.
The sleep diary about your sleeping habits.
It should take about 5 minutes each day to make entries in the study diaries. You will return the diaries to the study staff at 2 weeks and 4 weeks.
You will also wear a watch that will measure your activity level for 24 hours a day while you are on study. You will return the watch to the study staff after you have completed the study.
Questionnaires:
You will complete a questionnaire about any symptoms you are having from the light therapy at the beginning of the study, at 1 week, at 2 weeks, and at 4 weeks. The questionnaire at 1 week can be done over the phone. It should take about 5 minutes to complete.
You will complete the following questionnaires at the beginning of the study, at 2 weeks, and at 4 weeks:
The Edmonton Symptom Assessment Scale. You will rate 10 symptoms such as tiredness, shortness of breath, pain, and nausea.
The FACIT-F questionnaire about how well you are able to perform the normal activities of daily living, your quality of life, and how tired you are.
The HADS questionnaire about your mood.
The Pittsburgh Sleep Quality Index about your sleep quality, how long you sleep, and any difficulties you are having when you are trying to sleep.
It should take about 25 minutes to complete all of the questionnaires.
Length of Study:
You will be on study for 28 days.
This is an investigational study. The use of light therapy in patients with difficulty sleeping is investigational. It is currently being used for research purposes only.
Up to 152 patients will take part in this study. All will be enrolled at M. D. Anderson.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Advanced Cancers
Keywords
Sleep Disturbances, Depression, Anxiety, Fatigue, Quality of life
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2, Phase 3
Interventional Study Model
Single Group Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
12 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Bright Light Therapy
Arm Type
Experimental
Arm Description
Daily Bright Light Therapy using Bright Light Litebook device for two 14 day periods.
Arm Title
Dim Red Light Therapy
Arm Type
Placebo Comparator
Arm Description
Daily Dim Red Light Therapy (placebo) using control Red Light Litebook device for 14 days then proceed to the open label phase and receive daily bright light for 14 days.
Intervention Type
Other
Intervention Name(s)
Bright Light Therapy
Intervention Description
30 minutes every day for 14 days. After enrollment on day 0, blinded phase of study intervention (i.e. daily bright light or red light) from day 1 to day 14+/-3, then proceed to the open label phase and receive daily bright light between day 15+/-3 and day 28+/-3.
Intervention Type
Other
Intervention Name(s)
Dim Red Light Therapy
Intervention Description
From day 1 to day 14+/-3, daily dim red light therapy for 30 minutes for 14 days where red light device accounts for placebo of the blinded phase of study intervention, then between day 15+/-3 and day 28+/-3 open label phase with daily bright light.
Intervention Type
Behavioral
Intervention Name(s)
Questionnaires
Other Intervention Name(s)
Survey
Intervention Description
Weekly
Intervention Type
Behavioral
Intervention Name(s)
Study Diaries
Other Intervention Name(s)
journal
Intervention Description
Daily logs
Intervention Type
Device
Intervention Name(s)
Red Light Litebook
Intervention Description
Control red light device produced by Litebook identical in appearance and dimensions to the bright light device, with the exception it emits at wavelength 680nm (i.e. red light) and at an intensity of 50 lux.
Intervention Type
Device
Intervention Name(s)
Bright Light Litebook
Intervention Description
Bright light device consists of 60 LEDs with spectral emission peak at approximately 464nm and fluorescent phosphors which provide a broader, secondary spectral peak near 564nm. Collectively the emitted light appears white.
Primary Outcome Measure Information:
Title
Effect of Bright Light Therapy on Sleep Disturbances Compared to Dim Red Light in Patients With Advanced Cancer Followed at a Palliative Care Outpatient Clinic at a Comprehensive Cancer Center
Description
Pittsburgh Sleep Quality Index (PSQI) measured at baseline and two weeks. The PSQI is a validated tool for insomnia, an effective instrument for measuring the quality and patterns of sleep using a 19-item questionnaire. It differentiates "poor" from "good" sleep by measuring seven areas: subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleeping medication, and daytime dysfunction over the last month. Each area is rated from 0-3 with the higher score reflecting more severe sleep complaints. The addition of all scores permits the analysis of the participant's overall sleep experience. The PSQI global score ranges from 0 to 21, with a score of 5 or greater indicating significant sleep disturbance.
Time Frame
Baseline and Day 14
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Advanced cancer patients seen in Supportive Care outpatient clinic at M.D. Anderson Cancer Center, with average sleep disturbance >=4 out of 10 for at least one week
Age 18 or greater
Karnofsky performance status score of >=40 at time of inclusion into study
Agrees to return to MD Anderson Cancer Center (MDACC) for follow-up visits
English speaking
Exclusion Criteria:
Persons with congenital blindness and self-reported acquired blindness (independent of the cause) with no light perception
Patients with a history of retinal disease
Patients with a current diagnosis of major depression disorder or generalized anxiety disorder
Patients who have received light therapy in the past either as part of treatment for other disorders or as a study subject
Patients currently on amiodarone, thiazide diuretics or epidermal growth factor receptor (EGFR) inhibitors (erlotinib, gefitinib, cetuximab, panitumumab)
Patients who are currently receiving ultraviolet A light/ultraviolet B light (UVA/UVB) therapy or tanning sessions at salons
Patients with a diagnosis of obstructive sleep apnea or narcolepsy
Patients with >2 hours of direct exposure to outdoor natural light per day (light exposure diary -- screening).
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Rony Dev, DO
Organizational Affiliation
M.D. Anderson Cancer Center
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of Texas MD Anderson Cancer Center
City
Houston
State/Province
Texas
ZIP/Postal Code
77030
Country
United States
12. IPD Sharing Statement
Links:
URL
http://www.mdanderson.org
Description
University of Texas MD Anderson Cancer Center Website
Learn more about this trial
The Use of Light Therapy for Managing Sleep Disturbances in Patients With Advanced Cancer
We'll reach out to this number within 24 hrs